Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis

Article Rheumatology

Isolation, Behavioral Changes, and Low Seroprevalence of SARS-CoV-2 Antibodies in Patients With Systemic Lupus Erythematosus or Rheumatoid Arthritis

Christian Ammitzboll et al.

Summary: Patients with chronic rheumatic diseases, such as SLE and RA, have lower seroprevalence of SARS-CoV-2 antibodies, but this comes at the expense of reduced physical activity, increased pain, disease activity, and symptoms of depression.

ARTHRITIS CARE & RESEARCH (2022)

Add to Collection

Article Microbiology

Comparison of 16 Serological SARS-CoV-2 Immunoassays in 16 Clinical Laboratories

Lene H. Harritshoj et al.

Summary: This study evaluated the diagnostic accuracy of 15 commercial and one in-house anti-SARS-CoV-2 assays in Danish laboratories. Most total antibody and IgG assays showed high sensitivity and specificity, with some overlap in confidence intervals. IgM results were more variable, with one assay demonstrating higher sensitivity and specificity.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

Add to Collection

Review Rheumatology

COVID-19 vaccination and antirheumatic therapy

Jack Arnold et al.

Summary: This article discusses the impact of immunosuppressive therapy on COVID-19 vaccination, proposing a suggestion to temporarily suspend treatment to improve vaccine effectiveness, and urging decisions on withholding immunosuppressive therapy to be made in advance without sufficient data support.

RHEUMATOLOGY (2021)

Add to Collection

Article Rheumatology

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

Ulf M. Geisen et al.

Summary: In this study, the efficacy and safety of anti-SARS-CoV-2 mRNA vaccines in immunosuppressed patients were compared with healthy controls. The results showed that all study participants developed antibodies, with lower IgG titres in patients compared to controls. Side effects were minimal and no disease flares were observed, demonstrating the efficiency and safety of mRNA vaccines in this cohort despite its small size.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Letter Medicine, General & Internal

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

Brian J. Boyarsky et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Rheumatology

Risk of Severe COVID-19 Infection in Patients With Inflammatory Rheumatic Diseases

Javier Bachiller-Corral et al.

Summary: The study found that patients with inflammatory rheumatic diseases accounted for 1.8% of the total hospitalized population. Patients with diseases such as rheumatoid arthritis, vasculitis, and systemic lupus erythematosus had a higher risk of hospitalization. Rheumatoid arthritis patients also showed a higher mortality rate in COVID-19, especially those treated with RTX.

JOURNAL OF RHEUMATOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

Joseph E. Ebinger et al.

Summary: Virus-specific antibody levels after a single dose of the BNT162b2 vaccine in individuals previously infected with SARS-CoV-2 are similar to levels after two doses of the vaccine in infection-naive individuals. Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.

NATURE MEDICINE (2021)

Add to Collection

Article Rheumatology

American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1

Jeffrey R. Curtis et al.

Summary: This study aims to provide guidance to rheumatology providers on the use of COVID-19 vaccines in patients with rheumatic and musculoskeletal diseases. Despite limited direct evidence, consensus statements from the task force offer guidance and recommendations for vaccination strategies for RMD patients.

ARTHRITIS & RHEUMATOLOGY (2021)

Add to Collection

Article Rheumatology

Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases

Rebecca Hasseli et al.

Summary: The study found that factors such as age, cardiovascular disease, interstitial lung disease/chronic obstructive pulmonary disease, chronic kidney disease, and long-term use of glucocorticoids were associated with an increased risk of hospitalization for COVID-19 in patients with inflammatory rheumatic and musculoskeletal diseases.

RMD OPEN (2021)

Add to Collection

Article Rheumatology

High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry

Claudia Diniz Lopes Marques et al.

Summary: The study found that age over 50, the use of glucocorticoids and cyclophosphamide for immunosuppression were associated with unfavorable outcomes of COVID-19. Treatment with tumor necrosis factor inhibitor may have been protective, perhaps leading to the occurrence of the COVID-19 inflammatory process.

RMD OPEN (2021)

Add to Collection

Review Rheumatology